Compare Canopy Growth Corp (CGC) vs Dow Inc (DOW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Canopy Growth Corp vs Dow Inc — how do they compare? Canopy Growth Corp trades at $1 (market cap $421.10M), while Dow Inc trades at $31.25 (market cap $22.58B). The key difference: Dow Inc is far larger — about 53.6× Canopy Growth Corp's market cap, and Dow Inc pays a 4.48% dividend while Canopy Growth Corp pays none. Which is the better fit depends on your goals.
| CGC | DOW | |
|---|---|---|
Market Cap | $421.10M | $22.58B |
Sector | Health | Basic Materials |
52-Week High | $1.92 | $41.87 |
52-Week Low | $0.86 | $20.65 |
Enterprise Value | $378.55M | $38.27B |
Dividend Yield | — | 4.48% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CGC trades at $0.95, down 1.86% in the last session, with a neutral technical signal and mixed analyst ratings (9 buy, 11 hold, 7 sell). The company reported Q1 2027 revenue growth of 13% year-over-year, beating estimates, but continues to post net losses. Recent news highlights expansion in European cannabis markets and cost-cutting efforts, while the stock remains volatile amid regulatory uncertainty.
Outlook is cautious due to persistent losses and high debt, though improving cash flow and revenue growth offer potential upside. Key risks include regulatory delays in U.S. cannabis rescheduling and competitive pressures. Investors should weigh the speculative nature against any positive regulatory catalysts.
DOW trades at $30.58, up 4.23% today, with a neutral technical signal and bullish moving averages. Recent earnings have consistently beaten estimates, but the company reported a net loss of -$2.62B in 2025, with declining revenue and negative profit margins. Cash flow from operations improved in 2025 to $1.03B, though debt levels have risen. The stock is trading below the analyst consensus price target of $35.11, with a mixed analyst rating of 33% buy, 53% hold, and 14% sell.
The outlook is cautious; while earnings beats and a dividend payment provide some support, persistent net losses, revenue declines, and rising debt pose significant risks. Investors should weigh the potential for operational turnaround against fundamental weaknesses and macroeconomic pressures on the chemicals sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Canopy Growth Corp
Canopy Growth, headquartered in Smiths Falls, Canada, cultivates and sells medicinal and recreational cannabis, and hemp, through a portfolio of brands that include Tweed, Spectrum Therapeutics, and CraftGrow. Although it primarily operates in Canada, Canopy has distribution and production licenses in more than a dozen countries to drive expansion in global medical cannabis and also holds an option to acquire Acreage Holdings upon U.S. federal cannabis legalization.
Read more on CGC →About Dow Inc
Dow Inc is a diversified chemical manufacturing company. It combining science and technology to develop innovative solutions that are essential to human progress. Dow's portfolio is comprised of six global business units, organized into three operating segments: Packaging & Specialty Plastics, Industrial Intermediates & Infrastructure, and Performance Materials & Coatings.
Read more on DOW →
